Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04162678 · ClinicalTrials.gov registry record
Fluid Biopsy for the Diagnosis of Lung Cancer
A clinical trial, sponsored by University of Southern California.
- Terminated
- Registry status
- 51
- Enrollment target
NCT04162678 is a clinical trial that was terminated before completion, run by University of Southern California. The registered enrollment target is 51 participants.
The verdict
NCT04162678 was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- 51 participants
- Enrollment target
Study Summary
This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
- OTHER Medical Chart Review
- PROCEDURE Liquid Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2024-12-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04162678
The ClinicalTrials.gov registry entry for NCT04162678 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04162678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04162678 about?
NCT04162678 is a clinical study titled "Fluid Biopsy for the Diagnosis of Lung Cancer". This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.
What is the current status of trial NCT04162678?
This trial is currently terminated. The enrollment target is 51 participants. The study started on 2020-01-13. Estimated completion is 2024-12-09.
What interventions are being tested in trial NCT04162678?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Medical Chart Review (OTHER), Liquid Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04162678?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.